Pulmonary drug delivery is a highly attractive topic for the treatment of infectious lung
diseases. Drug delivery via the pulmonary route offers unique advantages of no first-pass …

Abstract Coronavirus disease 2019 (COVID-19) is a consequence of infection of the upper
and lower respiratory tract with severe acute respiratory syndrome coronavirus 2 but often …

Background Neurological symptoms such as cognitive decline and depression contribute
substantially to post-COVID-19 syndrome, defined as lasting symptoms several weeks after …

SARS-CoV-2 variants of concern (VOC) have triggered infection waves. Oral antivirals such
as molnupiravir promise to improve disease management, but efficacy against VOC delta …

SARS-CoV-2 has caused a global pandemic of COVID-19 since its emergence in December
2019. The infection causes a severe acute respiratory syndrome and may also spread to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its …

Several drug screening campaigns identified Calpeptin as a drug candidate against SARS-
CoV-2. Initially reported to target the viral main protease (Mpro), its moderate activity in Mpro …

Breast milk has been found to inhibit coronavirus infection, while the key components and
mechanisms are unknown. We aimed to determine the components that contribute to the …

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) possesses a
discriminative polybasic cleavage motif in its spike protein that is recognized by the host …

As the COVID‐19 pandemic grows, several therapeutic candidates are being tested or
undergoing clinical trials. Although prophylactic vaccination against SARS‐CoV‐2 infection …